June 15, 2019 @ 7:00 am – 5:15 pm
JB Duke Hotel
230 Science Dr
Durham, NC 27705
MAHEC Registration Team

Duke Physician Assistant Program MAT Waiver Training

The “Drug Addiction Treatment Act of 2000” created the opportunity to expand treatment for opioid use disorder into the mainstream of medical practice, increase the number of persons treated, and have an important positive public health impact. The legislation specifies several ways in which physicians can be considered qualified to prescribe and dispense buprenorphine in their offices for the treatment of opioid use disorder. The completion of this training fulfills the requirement prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid use disorder.

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in an office-based setting. The goal of this training is to acquire the knowledge and skills needed to provide optimal care to opioid use disorder patients by providing:

1) an overview of opioid use disorder
2) the efficacy and safety of buprenorphine
3) process of patient selection
4) clinical use of buprenorphine
5) nonpharmacological interventions
6) medical psychiatric conditions in opioid use disorder patients
7) office procedures
8) special treatment population

In total this eight hour training will include eight separate modules and four case studies. The speaker will be presenting for six hours. The remaining two hours is broken up over four case studies.

Designated by the DHHS, this training meets the eight-hour requirement and is designed for physicians to dispense buprenorphine in office practice for treatment of opioid use disorder. Participation in this training will provide physicians with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting. This training is designed for physicians and other primary care providers who are likely to treat opioid dependent persons in their practice, such as those in family practice, general internal medicine, psychiatry, pediatrics, adolescent medicine specialists, and Opioid Treatment Programs.

Target Audience

Residents, faculty, and other interested prescribers


  • Review addiction identification and evidence-based treatments
  • Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients
  • Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient
  • Explain the process of buprenorphine induction as well as stabilization and maintenance
  • Discuss other approved antagonist and agonist medications to treat OUD
  • Discuss basic office protocols including medical record documentation and confidentially
  • Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD
  • Apply for a MAT Waiver Training Certificate to begin treating patients with OUD


  • James W. Finch, MD FASAM
7:00am-8:00am Registration and Sign-In
8:00am-8:30am Overview
8:30am-9:00am Neurobiology
9:00am-10:00am Patient Evaluation
10:00am-10:45am Small Group / Case #1:  ADDICTED SCHOOL TEACHER


10:45am-11:00am BREAK
11:00am-11:45am Pharmacology
11:45am-12:15pm Specialty Topics
12:15pm-1:15pm LUNCH
1:15pm-2:00pm Medication Assisted Treatment (MAT) and Urine Drug Testing
2:00pm-2:45pm Small Group / Case #2:  ADDICTION AND DEPRESSION


2:45pm-3:25pm Evidence-Based Counseling
3:25pm-4:00pm Clinical Management
4:00pm-4:45pm Small Group / Case #3:  SETTING TREATMENT GOALS

Small Group / Case #4:  COCAINE ABUSE PROBLEM


4:45pm-5:15pm Completion of DEA Waiver; Questions and Answers; Evaluations
5:15pm-5:30pm Sign-Out

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA.  The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.